RE: RE: 2 out of 129Jasl,
Urocidin is already fast tracked, but I've come to learn that a fast track designation has more to do with the requested trial endpoint (and the fact that said endpoint supports faster data analysis) than anything the FDA recognizes as a treatment for good.
Also, I've come to learn that with surrogate endpoints like DFS, it is standard practice to have two or more PIII trials. Reason being, the endpoints are statiscal extrapolations unlike overall survivability with is pretty much back and white. Either way, a second PIII has always been on the books so it's pointless to debate why we need it.....
In the end, the PIIIa results are glowing, there is no debate about that. The fun in the debate comes from why the heck is our SP languishing. That is something that makes no sense.....
McRae had better not take a buyout (human health of otherwise) at a now premium price of $3-4......the only winner here (outside of Charlie Sheen who apparently always wins irrespective of topic) is Endo. I have to think they can't believe their luck when looking at BNC and what it would take to buy this out. At the rate, they might as well wait another 6 mos, have the price fall below Art's languish price and offer a real honey pot deal of $2....